Accelerate Diagnostics, Inc. (AXK) Quote

Just an opinion in that I'm too tied up in other stocks But if I were into AXK wxpecting a steady rise - I'd have a long term hold position and a flip position as it looks like an UP in the morning and down in the afternoon stock to me. Thats what I'd do. Good luck to you on how you handle it.

Just like any other stock that expects good news. A steady rise.

Just for fun do you have a WAG as to what AXK will be doing for that couple of months wait?

The product is completely developed and proven very reliable. What it lacks is FDA approval which could take couple of months, then marketing.

grawsha - Have no argument with your take on AXK. For longs though its timing as when to get in. Short term up/down because of that release is going to be hard to predict. My own is that AXK will be back under $2 before it goes above $4. Really need more info as to thier plans to make a better call so for right now its more of a gut play. GLTU

Those guys have invested in real company with real products. They are here to make a ton of money. They could easily drive the stock much higher just based on expectations and sell there.

I just crapped out of this symbol. Buy PVSP peeps. gltya.

Down on low volume.

Bounce sweetie

Being that I only STARTED learning about AXK this morning I can be neither LONG nor SHORT yet. Just posted a math opinion. Which also infers that if the full $35m is invested , they could sell above $4 , get thier money back and still controll the company. Beyond that it depends on the marketability of the company products as to weither this company sinks or swims. All need to do DD on that and decide.

"if you pay more than $1.25 a share IMO you are OVER PAYING"
Those guys didn't pay all that money to make mere 100% gain. They paid that amount of money to get much bigger return. Heck, this stock was $8 just mid last year. Try again, short.

Double again???? Read today's 8K filing. The $35m is in the form of about $14m for 14m shares at $1.03 plus 7m warrents with rights to purchase at exercise price of $1.03 and another 7m warrents with rights to purchase at $2. If all warrents are exercised that gets them 28m shares altogether at average cost of $1.25. The close on Monday was $2.51. So currently if you pay more than $1.25 a share IMO you are OVER PAYING short term.

$35 million invested into AXK.

Huge news. Talked about on cnbc. This didn't even start moving until after three yesterday. This should double easily today. imo.

On the contrary, after the positive dissemination of news, when the stock does once again open for trading, it more than likely will be up even more than its closing trade today.

Figured more folk would be here by now.

Halted??!! Oh Lordy, Lordy now we wait to see why.

Thx Gixxer, appreciate that.

Just noticed this stock has been halted...hope everyone got out today in time after the nice move up!

I was ready to but 10k shares @1.50 scottrade won't trade axk

I'm pist - as soon as cnbc talked about it off to the races all I could do was watch .. Oh well GLTY guys that got in

8 "followers" now.

Looking Good peeps!

$20k the right way:)

Boom - you can thank cnbc lol

Recent quarterly reporting about capital level and requirement!


"The Company has historically funded its operations generally through its existing cash balances, cash flow generated from operations and sales of equity securities. Our primary use of capital has been for the research and development of the BACcel(TM) system.

Notwithstanding our investments in research and development, there can be no assurance that the BACcel(TM) system or any of our other products will be successful, or even if they are successful, will provide sufficient revenues to continue our current operations.

Our working capital requirements are expected to increase in line with the growth of our business. We have no lines of credit or other bank or off balance sheet financing arrangements. We believe that the plan of operations for the next twelve months will require additional capital of approximately $600,000. Management believes that current cash balances plus cash flow from operations will not be sufficient to fund our capital and liquidity needs for the next twelve months and we will be required to obtain additional capital through the issuance of debt or equity securities or other means to execute our plans. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all. Additional issuances of equity or convertible debt securities will result in dilution to our current common stockholders. "

I don't know. I could be short covering.

What is going on here today?????

It looks like the selloff was caused by no obvious reason, except some big holder sold out of AXK.

no clue
I sent off an email to someone who is big in AXK. If I find out anything I shall post.

Any idea why is't falling hard?

Just a rumor. Buyout rumors abound in the bio techs.

Is that a rumor or solid info w/link?

Rumor is that NOVARTIS is going to buy them out and that announcement could come as early as the end of June or possibly July.

Good to see some PPS move by EOD.

Accumulation.

Nice profit-taking day.

Accelr8 4-Hour Test Identifies New Drug-Resistant “Staph” (hVISA) Undetectable by Hospital Labs
Date : 05/23/2011 @ 7:00AM
Source : Business Wire
Stock : Accelr8 Technology Corporation (AXK)
Quote : 4.701 0.061 (1.31%) @ 9:29AM

Accelr8 4-Hour Test Identifies New Drug-Resistant “Staph” (hVISA) Undetectable by Hospital Labs
Accelr8 (AMEX:AXK)
Intraday Stock Chart
Today : Monday 23 May 2011


Accelr8 Technology Corporation (NYSE Amex: AXK) announced results from two studies presented at ASM 2011 (American Society for Microbiology, www.asm.org) held in New Orleans. Authors included principal investigators from Denver Health and from the Barnes-Jewish Hospital in St. Louis. The annual ASM General Meeting is a major international congress for microbiologists and Infectious Diseases physicians.

One study screened 281 randomly collected clinical specimens and identified 62 for complete detailed analysis of pathogen content. The purpose was to test the accuracy and timing for BACcel™ rapid diagnostic assays intended for use with critically ill patients who acquire serious infections. The BACcel™ system eliminates culturing and analyzes individual live microbial cells directly from a patient specimen. All specimens came from the lower respiratory tract, used to diagnose pneumonia and other severe lung or bronchial infections. Hospital acquired pneumonia is the leading infectious cause of death in ICUs.

The study targeted three major pathogenic bacterial species responsible for infections multi-drug resistance (MDR). Together, these three species account for more than half of hospital acquired MDR infections. They include Staphylococcus aureus (“Staph,” including MRSA), Pseudomonas aeruginosa, and Acinetobacter species. The latter two organisms already have high MDR propensity. But investigators are now finding new strains that recently acquired novel, rapidly-spreading “superbug” KPC genes from entirely unrelated species.

The new ASM study reported that the total time from specimen to results only required 4 hours, instead of the typical 3-day time for cultures using the same specimens. Results included organism counts, identification, and expression of two major resistance types for each one, including MRSA. Identification was correct in 182 of 186 tests, and antibiotic resistance classification in 31 of 32 tests.

The second study characterized Accelr8’s new test for a hidden type of resistance in “Staph.” Not only MRSA, but also the more common type of Staph can effectively resist the standard anti-MRSA antibiotic, vancomycin. With a new type of strain known as hVISA, culturing tests indicate susceptibility to vancomycin, but fails to detect subtle indications of low-level resistance that can lead to treatment failure. Microbiologists refer to this type of cryptic behavior as “heteroresistance.”

The investigators screened Staph clinical isolates (laboratory strains) and found 15 hVISA using complex culturing methods. The new BACcel™ assay correctly classified 14 of the 15 as hVISA, and 14 of 14 Staph clinical isolates negative for cryptic resistance.

Culturing methods to detect hVISA take 3 days or longer, depending on the methods. The BACcel™ system produced results in 4 hours. The test can be used directly from patient specimens, which would add no more than 1 hour to the total processing time.

According to David Howson, Accelr8’s president, “the specimen study used types of specimen that may be the most difficult specimens for a lab to analyze. They are highly variable, and contain large amounts of sticky and bulky interfering materials. In the past, new diagnostic tests that have worked well with cultured strains often failed when challenged directly with respiratory specimens. We believe this study demonstrates that we’ve overcome this major hurdle. The study also set a new speed record for counting, identifying, and analyzing multiple targets with multiple resistance tests—only four hours after starting with a specimen. If we consider these results and the results presented a week ago at ATS, the combined data show that the BACcel™ rapid diagnostic system is accurate and very fast.”

“The hVISA study also follows a presentation three weeks ago at the European ECCMID meeting that used the BACcel™ hVISA test, along with others. The new results add details that more fully characterize the test performance with this difficult new strain. The ASM study demonstrates the BACcel™ system’s potential for revealing fundamental modes of resistance expression that were neither predicted nor detected using standard culturing methods,” Howson continued.

“These and other tests for multiple organisms and multiple resistance expression modes provide the platform for expanded studies and integration into the next BACcel™ generation. We are now widening our key opinion leader network to prepare for these important studies,” Howson concluded.

Downloadable copies of presentations are available on the publications page of Accelr8’s Web site at www.accelr8.com/pgen.php?pg=resources_publications.

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel™ system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8’s own products.

Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.

Way oversold imo. Within 2 weeks, this imo is back close to or over $2.00.

way oversold especially in this sector.

*** ONE STOP DD! ***
http://www.finviz.com/quote.ashx?t=AXK&ty=c&ta=1&p=d&b=1